The Oncologist, Vol. 11, No. 6, 553-562, June 2006; doi:10.1634/theoncologist.11-6-553 © 2006 AlphaMed Press
Aromatase Inhibitors in Breast Cancer: An Overviewa Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA; b Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey Key Words. Breast cancer • Hormone receptor-positive • Aromatase inhibitor Correspondence: Nuhad K. Ibrahim, M.D., Department of Breast Medical Oncology, Unit 424, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030-4009, USA. Telephone: 713-792-2817; Fax: 713-794-4385; e-mail: nibrahim{at}mdanderson.org
We examined published reports on the use of aromatase inhibitors in postmenopausal patients with hormone receptor-positive breast cancer. Our data were obtained through a MEDLINE search of literature published in English. Current data indicate that aromatase inhibitors are equivalent or superior to tamoxifen as first-line therapy for metastatic breast cancer and as neoadjuvant treatment for primary breast cancer. In addition, randomized studies have shown that aromatase inhibitors can be administered instead of tamoxifen as a single agent for 5 years or sequentially with tamoxifen for 5 or 10 years. These choices should be discussed with the patient, considering the estimated risk for recurrence and other associated comorbid conditions such as osteoporosis and thromboembolism.
This article has been cited by other articles:
Copyright © 2006 by AlphaMed Press. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||